Ally Biotech Acquires THC 'Chill Pill' Soft Gel Cap Line From Desert Medical Campus

Ally Biotech announced the acquisition of the Chill Pill brand, a line of soft, soft gel caps and all of its assets, from Desert Medical Campus, in an all-cash transaction.

Company president, Jim Mackowiak, said plans are underway to expand the Chill Pill line to include new products that are developed with highly bioavailable custom formulations. “The new wave of cannabis consumers value rapid-onset products that are consistent and safe,” he said.

The company’s VP of business development, Francis Baczek agrees.

“Chill Pill provides a great delivery system for a consistently accurate dose. We are excited to add new products, expand our team, and bring our improved science and technology to the growth of our business and our brands,” stated Baczek. “We have seen tremendous success with the Chill Pill brand because consumers rely upon its products’ accurate dosing, convenience, consistency, and predictable therapeutic effects. Ally Biotech will continue building upon our strong vision for both the medical and adult-use markets, and is well poised to expand the brand successfully.”

The Chill Pill soft gel cap line includes:

• Day Caps – a sativa-dominant formula.

• Anytime Caps – a formulation that combines sativa and indica.

• Night Caps – an indica dominant formula.

• Anytime Caps + CBD – a 1:1 blend of THC and CBD.

• THC-A – Non-intoxicating symptom relief with no psychoactive effects.

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Esteban López on Unsplash